(1S,3aS,4R,7R,8aR)-1,4-Dihydroxy-4-(hydroxymethyl)-1-methyl-7-(2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)propan-2-yl)octahydroazulen-2(1H)-one
- Catalog No. :
- ACFWUT280
- CAS No. :
- 126054-77-1
- Molecular Formula :
- C21H36O10
- Molecular Weight :
- 448.51
IUPAC Name:(1S,3aS,4R,7R,8aR)-1,4-dihydroxy-4-(hydroxymethyl)-1-methyl-7-(2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)propan-2-yl)octahydroazulen-2(1H)-one
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5mg98%$68.00Login to see priceInquiryInquiry
10mg98%$109.00Login to see priceIn stockInquiry
25mg98%$219.00Login to see priceInquiryInquiry
50mg98%$328.00Login to see priceInquiryInquiry
Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.
0 Reviews:View Reviews
Product Information
| Product Name | (1S,3aS,4R,7R,8aR)-1,4-Dihydroxy-4-(hydroxymethyl)-1-methyl-7-(2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)propan-2-yl)octahydroazulen-2(1H)-one |
|---|---|
| IUPAC Name | (1S,3aS,4R,7R,8aR)-1,4-dihydroxy-4-(hydroxymethyl)-1-methyl-7-(2-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)propan-2-yl)octahydroazulen-2(1H)-one |
| MDL No. | - |
| Molecular Formula | C21H36O10 |
| Molecular Weight | 448.51 |
| SMILES | O=C1[C@@](C)(O)[C@]2([H])C[C@H](C(C)(O[C@H]3[C@@H]([C@H]([C@@H]([C@@H](CO)O3)O)O)O)C)CC[C@@](CO)(O)[C@@]2([H])C1 |
| InChI Key | QNBLVYVBWDIWDM-BSLJOXIBSA-N |
| Synonym | (3S,3aR,5R,8R,8aS)-3,8-dihydroxy-8-(hydroxymethyl)-3-methyl-5-[2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl]-3a,4,5,6,7,8a-hexahydro-1H-azulen-2-one | AtractylosideA | AC-34082 | BS-14865 | CHEBI:138832 | AKOS030526368 | |
| CAS No. | 126054-77-1 |
| PubChem CID | 71307451 |
Safety Data
- Pictogram
- Signal Word
- Warning
- Hazard Statement(s)
- H302-H315-H319-H335
- Precautionary Statement(s)
- P261-P305+P351+P338
